Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. The effect of liraglutide on natriuretic peptides and copeptin in heart failure patients

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  2. Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Rationale and design of the European multicentre study on Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE (SCIENCE)

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. "Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation"

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Duration of Heart Failure and Effect of Defibrillator Implantation in Patients With Nonischemic Systolic Heart Failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Mortality and morbidity of major congenital heart disease related to general prenatal screening for malformations

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Heart failure with preserved or mildly reduced ejection fraction (HFpEF) is common and, to date, therapeutic options are limited. Increased left atrial pressure is a key contributor to the symptoms associated with HFpEF, particularly during physical activity. We report the 30-day outcome of patients treated with a novel device intended to lower left atrial pressure by creating an 8 mm permanent shunt in the atrial septum.

METHODS AND RESULTS: Eleven patients were enrolled in the pilot trial. Key inclusion criteria were: EF >45%; baseline PCWP ≥15 mmHg (rest), or ≥ 25 mmHg (exercise); and ≥1 hospitalization for heart failure within the past 12 months, or persistent NYHA class III/IV for at least 3 months. Mean age, LVEF, and NYHA class were 70 ± 12 years, 57 ± 9%, and 3.2 ± 0.4, respectively. Most patients had significant co-morbidities. The interatrial septal device (IASD) device was implanted using percutaneous trans-septal access via the femoral vein. The device was successfully implanted in all patients. At 30 days, LV filling pressures were significantly reduced by 5.5 mmHg (19.7 ± 3.4 vs. 14.2 ± 2.7; P = 0.005), and NYHA class was improved by two classes in two patients, one class in five patients, and worsened by one class in one patient. No patient developed pulmonary hypertension. Two serious adverse events occurred; heart failure re-hospitalization, and implant malposition successfully treated with a new device.

CONCLUSION: Contemporary management of HFpEF patients is confounded by the lack of effective therapies. The use of a device-based approach to reduce left atrial pressure provides a novel means to improve haemodynamic and symptomatic status in HFpEF patients and warrants further investigation.

Original languageEnglish
JournalEuropean Journal of Heart Failure
Volume16
Issue number7
Pages (from-to)796-801
Number of pages6
ISSN1388-9842
DOIs
Publication statusPublished - Jul 2014

ID: 45026687